Clinical application of rhG-CSF in chemotherapy for solid tumors
1Department of Oncology, Central Hospital of China TIESIJU Civil Engineering Group CO.LTD, Heifei 230022; 2Dept of Oncology, the Affiliated Provincial Hospital of Anhui Medical University, Heifei 230001ZHAO Wen-jie1, WANG Yong2, HU Chang-lu2
Objective To investigate the proper interval between chemotherapy for solid tumors and recombinant human granulocyte colony stimulating factor(rhG-CSF) administration.Methods Thirty patients who received chemotherapy and rhG-CSF injection were randomly divided into two groups,15 patients in group A were given rhG-CSF 24 hours after chemotherapy, another 15 patients in Group B were given rhG-CSF only when the white blood cell counts (WBC) dropped to 2×109/L. Results Both could effectively prevent bone marrow depression and fulfill the treatment, but the average amount of the drug in group B was 3.69 compared with 6.17 in group A, which showed statistically difference between them(P0.01). Conclusion Different applications of rhG-CSF have almost the same efficacy, while showing statistical difference in economics, which needs further study.
【CateGory Index】： R730.5